



## Human PD-1 Monoclonal Antibody (Research Grade Nivolumab Biosimilar)

Recombinant Monoclonal Human IgG1 Clone #FB008

Catalog Number: BIO-014

### DESCRIPTION

Species Reactivity	Human
Specificity	Detects human PD-1 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Nivolumab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG4 S228P Clone #FB008
Purification	Protein A/G purified from CHO cell culture supernatant
Immunogen	Human PD-1
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method
Formulation	0.2 µm filtered solution in PBS

### APPLICATION

	Recommended Concentration
Flow Cytometry	0.25 µg/10 <sup>6</sup> cells

### PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/ml in sterile 1xPBS
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"><li>• 12 months from the date or receipt, -20 to -70°C as supplied.</li><li>• 1 month, 2 to 8°C under sterile conditions</li></ul>

### BACKGROUND

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. As a PD-1 blocking antibody, Nivolumab is used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.